Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with substantial healthcare resource use, particularly when recipients develop cytomegalovirus (CMV) infection. Letermovir reduced post-HSCT CMV infection risk compared with placebo in a previous phase III trial. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Golan, Yoav, Tang, Yuexin, Mt-Isa, Shahrul, Wan, Hong, Teal, Valerie, Badshah, Cyrus, Dadwal, Sanjeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333192/
https://www.ncbi.nlm.nih.gov/pubmed/33871830
http://dx.doi.org/10.1007/s41669-021-00264-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8333192/
https://www.ncbi.nlm.nih.gov/pubmed/33871830
http://dx.doi.org/10.1007/s41669-021-00264-9

Ejemplares similares